EP3749367A4 - Utilisation d'un anticorps monoclonal ghr-106 en tant qu'antagoniste de gnrh - Google Patents

Utilisation d'un anticorps monoclonal ghr-106 en tant qu'antagoniste de gnrh Download PDF

Info

Publication number
EP3749367A4
EP3749367A4 EP19751462.3A EP19751462A EP3749367A4 EP 3749367 A4 EP3749367 A4 EP 3749367A4 EP 19751462 A EP19751462 A EP 19751462A EP 3749367 A4 EP3749367 A4 EP 3749367A4
Authority
EP
European Patent Office
Prior art keywords
ghr
monoclonal antibody
gnrh antagonist
gnrh
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19751462.3A
Other languages
German (de)
English (en)
Other versions
EP3749367A1 (fr
Inventor
Gregory Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vancouver Biotech Ltd
Original Assignee
Vancouver Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vancouver Biotech Ltd filed Critical Vancouver Biotech Ltd
Publication of EP3749367A1 publication Critical patent/EP3749367A1/fr
Publication of EP3749367A4 publication Critical patent/EP3749367A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19751462.3A 2018-02-06 2019-02-05 Utilisation d'un anticorps monoclonal ghr-106 en tant qu'antagoniste de gnrh Pending EP3749367A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862627052P 2018-02-06 2018-02-06
PCT/CA2019/050147 WO2019153075A1 (fr) 2018-02-06 2019-02-05 Utilisation d'un anticorps monoclonal ghr-106 en tant qu'antagoniste de gnrh

Publications (2)

Publication Number Publication Date
EP3749367A1 EP3749367A1 (fr) 2020-12-16
EP3749367A4 true EP3749367A4 (fr) 2021-12-01

Family

ID=67548725

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19751462.3A Pending EP3749367A4 (fr) 2018-02-06 2019-02-05 Utilisation d'un anticorps monoclonal ghr-106 en tant qu'antagoniste de gnrh

Country Status (8)

Country Link
US (1) US11021541B2 (fr)
EP (1) EP3749367A4 (fr)
JP (1) JP2021512957A (fr)
KR (1) KR20200118092A (fr)
CN (2) CN111727055B (fr)
BR (1) BR112020015880A2 (fr)
CA (1) CA3090335A1 (fr)
WO (1) WO2019153075A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351642A4 (fr) * 2021-05-18 2025-04-23 Vancouver Biotech Ltd. Applications d'un anticorps monoclonal ghr-106 en tant qu'antagoniste de gnrh

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119519A1 (fr) * 2017-01-01 2018-07-05 Lee Chi Yu Gregory Construction d'un récepteur antigénique chimérique ghr-106, et procédés de fabrication et d'utilisation de ce dernier

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2194064A1 (fr) * 2004-05-13 2010-06-09 Eli Lilly & Company Protéines de fusion FGF-21
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN101864398B (zh) * 2009-09-03 2012-11-14 李吉祐 一种抗促性腺激素释放激素受体的单克隆抗体与应用
US8163283B2 (en) * 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US9273138B2 (en) * 2012-07-27 2016-03-01 Vancouver Biotech Ltd. Humanized forms of monoclonal antibodies to human GnRH receptor
CN108484778B (zh) * 2017-03-31 2022-03-29 李吉祐 人源化ghr106单克隆抗体的嵌合抗原受体构建体及核酸分子与应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119519A1 (fr) * 2017-01-01 2018-07-05 Lee Chi Yu Gregory Construction d'un récepteur antigénique chimérique ghr-106, et procédés de fabrication et d'utilisation de ce dernier

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GREGORY LEE ET AL: "CA215 and GnRH receptor as targets for cancer therapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 61, no. 10, 21 March 2012 (2012-03-21), pages 1805 - 1817, XP035115252, ISSN: 1432-0851, DOI: 10.1007/S00262-012-1230-8 *
GREGORY LEE ET AL: "Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 59, no. 7, 25 February 2010 (2010-02-25), pages 1011 - 1019, XP019800218, ISSN: 1432-0851 *
JOHN-PAUL SILVA ET AL: "The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 9, 27 February 2015 (2015-02-27), US, pages 5462 - 5469, XP055299482, ISSN: 0021-9258, DOI: 10.1074/jbc.M114.600973 *
LEE GREGORY ET AL: "Humanized GHR106 Monoclonal Antibody is a Biosimilar GnRH Antagonist", INVESTIGATIONS IN GYNECOLOGY RESEARCH & WOMENS HEALTH (IGRWH), vol. 1, no. 5, 6 April 2018 (2018-04-06), XP093133324, ISSN: 2577-2015, Retrieved from the Internet <URL:https://crimsonpublishers.com/igrwh/pdf/IGRWH.000524.pdf> DOI: 10.31031/IGRWH.2018.01.000524 *
See also references of WO2019153075A1 *

Also Published As

Publication number Publication date
US11021541B2 (en) 2021-06-01
US20200354462A1 (en) 2020-11-12
EP3749367A1 (fr) 2020-12-16
CN118557719A (zh) 2024-08-30
CA3090335A1 (fr) 2019-08-15
CN111727055A (zh) 2020-09-29
WO2019153075A1 (fr) 2019-08-15
CN111727055B (zh) 2024-06-25
BR112020015880A2 (pt) 2020-12-08
JP2021512957A (ja) 2021-05-20
KR20200118092A (ko) 2020-10-14

Similar Documents

Publication Publication Date Title
IL283812B (en) Humanized antibody against human pd–1
IL291068A (en) Anti-cd73 antibodies
IL289112A (en) Antibodies against tigit
GB201905150D0 (en) Ant-ige antibodies
ZA202205226B (en) Ri-labeled humanized antibody
EP4083211A4 (fr) Anticorps anti-cdcp1
ZA202108836B (en) Anti-epha4 antibody
IL284584A (en) Anti-tigit antibodies
IL278962A (en) Antibody against human TRL7
IL276937A (en) Using an antibody against P-selectin
EP3862366A4 (fr) Anticorps spécifique de cellules souches cancéreuses
GB201911211D0 (en) Monoclonal antibodies against ambra-1
EP3766898A4 (fr) Anticorps reconnaissant cadm1 v9
GB201900732D0 (en) Antibodies
EP3749367A4 (fr) Utilisation d&#39;un anticorps monoclonal ghr-106 en tant qu&#39;antagoniste de gnrh
GB201919062D0 (en) Antibody
GB201917480D0 (en) Antibodies
SG11201913540VA (en) Anti-Podoplanin Antibody
GB201910138D0 (en) Anti-pd-l1 antibodies
IL289160A (en) Anti-angpt2 antibodies
EP4070816A4 (fr) Anticorps anti-gdf15
PL4025612T3 (pl) Przeciwciała anty-fukozylo-gm1
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
HK40077343A (en) Amh-competitive antagonist antibody
HK40058314A (en) Use of anti-fam19a5 antibodies

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200810

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20211028

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/46 20060101ALI20211022BHEP

Ipc: C07K 16/28 20060101ALI20211022BHEP

Ipc: A61P 35/00 20060101ALI20211022BHEP

Ipc: A61K 39/395 20060101AFI20211022BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240229